NuSep licences gels

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.

The third party had offered to acquire NuSep's gels business outright or to license the technology.

It was decided that licensing the technology would provide the best return for shareholders, the company said.

The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.

NuSep also supplies research grade biological products such as human IgG and albumin.

Related News

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd